The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

today announced that it will present new data from the safety run-in portion of its ongoing trial evaluating BI-1206 in combination with rituximab and Calquence ® (acalabrutinib) for the treatment of ...

WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult ...

ELEVATE-RR head-to-head trial data also presented at ASH showed patients on ibrutinib experienced a 37% higher burden of adverse events of any grade while on treatment vs. patients on CALQUENCE ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with ...

When AstraZeneca ended a late-stage trial for Calquence early after seeing promising results, the news boded well for the drug’s chances in previously treated chronic lymphocytic leukemia (CLL). Now, ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s CALQUENCE® (acalabrutinib) in ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL). Now, AZ has new ...

AstraZeneca (AZ) has announced that its Calquence (acalabrutinib) regimens have been recommended by the European Medicines Agency’s human medicines committee to treat chronic lymphocytic leukaemia ...

Late in the afternoon on the first Friday of April, Andrew Monticelli, an oncologist at Rocky Mountain Cancer Centers, got a phone call from Jeff Sharman, the medical director of hematology research ...

WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the ASCEND Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) maintained a statistically significant progression-free survival ...